Status:
ENROLLING_BY_INVITATION
An Investigational Study Examining the Cross-Validation of QbMobile in ADHD and Normative Populations
Lead Sponsor:
Qbtech AB
Conditions:
No History of ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
Eligibility:
All Genders
6-60 years
Brief Summary
The purpose of this study is to investigate QbMobile ability to collect and provide accurate and objective data which can be used to facilitate assessment and treatment procedures for ADHD in a clinic...
Detailed Description
This study aims to evaluate the performance of QbMobile in children, adolescents, and adults from the normative population, those referred for an initial ADHD assessment, and individuals with an ADHD ...
Eligibility Criteria
Inclusion
- Provide written informed consent (including parent/legal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile;
- Aged \> 6 years and \< 60 years old;
- Have no documented or suspected current or lifetime diagnosis of ADHD or referred for an initial assessment for ADHD or have a diagnosis of ADHD but not currently receiving treatment;
- Meet DSM-5 or ICD-11 criteria for a primary diagnosis of ADHD (combined, inattentive, or hyperactivity/impulsive presentation) per sites standard clinical care evaluation;
- Qbtech Rating Scale total score of \>24 at Visit 1;
- Have adequate sensory and physical ability to complete QbMobile;
- Possess or has access to an iPhone model that supports QbMobile.
Exclusion
- Intellectual disability designated by IQ\<75;
- Has used psychostimulant medication within the past 7 days prior to Visit 1;
- A current medical diagnosis that could significantly affect test performance (brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g., vascular dementia, Alzheimer disease, etc.);
- Other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain);
- Substance use (e.g., alcohol, drugs) that may affect performance on the day of the tests.
Key Trial Info
Start Date :
January 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT07220330
Start Date
January 15 2025
End Date
October 1 2026
Last Update
December 31 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Prodigy Psychiatric Group
San Jose, California, United States, 95138
2
Bokhari Medical Consortium
Largo, Florida, United States, 33770
3
Nona Pediatric Center
Orlando, Florida, United States, 32832